Study identifier:D5392NL003
ClinicalTrials.gov identifier:NCT00301457
EudraCT identifier:N/A
CTIS identifier:N/A
A prospective randomised, open, multicentre, phase III study to assess different durations of anastrozole therapy after 2 to 3 years tamoxifen as adjuvant therapy in postmenopausal women with breast cancer.
Breast Cancer
Phase 3
No
Anastrozole
Female
1914
Interventional
45 Years - 99 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 May 2016 by AstraZeneca
AstraZeneca
-
The purpose of this study is to determine whether 6 years adjuvant anastrozole will improve the disease free survival compared to 3 years adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2-3 years tamoxifen
Location
Location
AMERSFOORT, Netherlands
Location
BREDA, Netherlands
Location
Den Bosch, Netherlands
Location
DORDRECHT, Netherlands
Location
VELDHOVEN, Netherlands
Location
EINDHOVEN, Netherlands
Location
GELDROP, Netherlands
Location
ALMELO, Netherlands
Arms | Assigned Interventions |
---|---|
Experimental: 1 6 years adjuvant anastrozole therapy | Drug: Anastrozole 1 mg once daily oral dose Other Name: ARIMIDEX Other Name: ZD1033 |
Experimental: 2 3 years adjuvant anastrozole therapy | Drug: Anastrozole 1 mg once daily oral dose Other Name: ARIMIDEX Other Name: ZD1033 |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.